The effectiveness of naloxone and nalbrphine in antagonizing the effects of fentanyl and droperidol on the hot plate reaction time and the respiratory rate of the mouse has been compared. Naloxone was superior to nalorphine, being a more effective antagonist, and was also free from significant agonist effects. However, neither antagonist was completely effective against the respiratory rate depression produced by combinations of fentanyl and droperidol. It is suggested that the duration of the antagonist effects of naloxone are shorter against respiratory depression than against analgesia.
Neuroleptanaesthesia has established itself as a very useful technique. Its major advantages include an uncomplicated induction, cardiovascular stability during maintenance of anaesthesia and a recovery phase characterized by a rapid return to consciousness and absence of restlessness and vomiting (Morgan, Lumley and Gillies, 1974) . However, the "ideal" anaesthetic agent should either have a short duration of action or have an effective antagonist. Neither criterion is truly satisfied by the drugs used during neuroleptanaesthesia, such as fentanyl and droperidol. Indeed, Morgan, Lumley and Gillies (1974) report that 18% of their patients did not establish adequate spontaneous ventilation at the end of anaesthesia. In addition, planned major operations may be terminated unexpectedly and so the search for an effective antagonist is of practical importance. Nalorphine has been used but is less than ideal (Foldes, Duncalf and Kuwabara, 1969) . It is a partial agonist and may cause respiratory depression and weak analgesia. It may also produce undesirable side-effects such as sedation, dysphoria and hallucinations.
Naloxone is a more recently developed narcotic antagonist, now released for clinical use in this country. It is reported to be between 10 and 15 times more potent as an antagonist than is nalorphine (Hasbrouck, 1971) and, in addition, is devoid of significant agonist effects (Foldes, Duncalf and Kuwabara, 1969; Evans et al., 1974a) .
Therefore it was decided to compare naloxone and nalorphine as antagonists for the drugs used during neuroleptanaesthesia. 
METHOD
Consecutive series of four groups each containing 12 male and female albino mice weighing 20-30 g were studied. The drugs used and the dose ranges of each are shown in tables I and II. Fentanyl and droperidol were used in the commercially available forms and, when used together, were used in the same dose ratio as in a commercially available combination. Naloxone was prepared from the pure compound supplied in powder form. In each experiment, one group of mice was injected i.p. with saline and acted as control; a second group was injected with fentanyl (with or without droperidol); a third group was injected with an antagonist alone, either nalorphine or naloxone; a fourth group was injected with a combination of that antagonist and the dose of fentanyl (with or without droperidol). At 15-min intervals thereafter observations were made, on each animal, of respiratory rate and the state of analgesia. Respiratory rate was measured by placing the mouse's snout in the barrel of a 5-ml syringe connected to a pressure transducer and pen recorder (Devices Ltd). Then analgesia was assessed by using the hot plate reaction time test as described by Bousfield and Rees (1969) . Any mouse not responding within 45 s was removed from the plate in order to avoid tissue damage.
The results were expressed as mean values (± SEM). The statistical significance of difference between means was assessed using Student's t test where applicable. In the case of non-parametric data, the Mann-Whitney U test was used.
RESULTS
The respiratory effects of each drug alone are shown in table I and the analgesic effects in table II. Fentanyl, droperidol and nalorphine all showed detectable depression of respiratory frequency, but whilst fentanyl and nalorphine also showed detectable analgesic activity, droperidol actually decreased hot plate reaction times. The changes associated with naloxone were never statistically significantly different from the control values.
The antagonist was considered effective when it reduced the maximal effects of fentanyl (with and without droperidol) to values not significantly different (P<0.05) from those associated with saline.
When considered against the highest doses of fentanyl alone (0.4 mg/kg and 0.8 mg/kg), no dose of nalorphine produced adequate reversal of respiratory depression. However, at the lowest dose of fentanyl (0.2 mg/kg) the lowest dose of nalorphine (5 mg/kg) provided adequate respiratory antagonism though larger doses of nalorphine (10 mg/kg and 20 mg/kg) were ineffective. Naloxone, however, proved highly effective in antagonizing the respiratory depression of all doses of fentanyl. This is illustrated by the results shown in figure 1 .
The antagonist effects of nalorphine against the analgesic effects of all doses of fentanyl were rather variable but largely inadequate. Naloxone, however, consistently completely reversed the analgesic effects of all doses of fentanyl, but this effect persisted against the larger doses of fentanyl (0.4 mg/kg and 0.8 mg/kg) for only about 30 min, there being an observable return of analgesia at 45-60 min. This effect was not prevented by increasing the size of the initial dose of naloxone, but was completely abolished by a second dose of naloxone at 30 min ( fig. 2) . Against a combination of fentanyl and droperidol, nalorphine and naloxone were both inadequate in reversing respiratory depression. Increasing the dose of nalorphine from 5 to 10 mg/kg in an attempt to improve the reversal made the depression considerably worse. This is illustrated in figure 3 , where the small depression of respiratory rate induced by fentanyl 0.1 mg/kg and droperidol 5 mg/kg is seen to have been increased by the addition of nalorphine 10 mg/kg. Increasing the dose of naloxone (up to 2 mg/kg) neither increased nor decreased the reversal of the respiratory effects of the fentanyl/droperidol combination ( fig. 4) .
The analgesic effects of the combination were reversed adequately without difficulty by both nalorphine and naloxone.
DISCUSSION
It is confirmed that in mice, as shown by Greene (1972) , the addition of droperidol significantly increased the respiratory rate depression produced by fentanyl. Since this study showed that droperidol 87 alone produced a small but significant depression of respiratory rate, this effect can be explained as being a result of simple summation (table I) . Corssen, Domino and Sweet (1964) found that, in humans, it appeared that the respiratory depressant effects of fentanyl were enhanced by droperidol, but the difference was not statistically significant.
On the other hand, the finding that droperidol increased the analgesic effects of fentanyl as measured by hot plate reaction time (table II) is very difficult to explain since droperidol alone did not show analgesic effects: in fact it appeared to be anti-analgesic (table II) . Keats and Telford (1966) found that the agonist effects of nalorphine increased with increasing dose up to a ceiling value. This effect occurred in this study in which the maximum analgesic and respiratory depressant effects occurred following the intermediate dose (10 mg/kg), both effects being significantly greater than those in the control group (P<0.02 and P< 0.005, respectively). Both effects were diminished at the lower and higher doses (5 mg/kg and 20 mg/kg). Displayed graphically, this would correspond to the typical form of the doseresponse curve of a partial agonist. It is noted that in a previous study, in mice, Pearl and Harris (1966) found no evidence of analgesic activity for nalorphine. This may be related to the fact that a different test of analgesia, the writhing test, was used.
At no time in this study did any dose of naloxone used show agonist effects significantly different from the control substance. This agrees with many previous reports such as those referred to above.
This study confirms also that, as has been shown by Foldes, Duncalf and Kuwabara (1969) , naloxone produces complete reversal of narcotic agonist effects whilst the reversal produced by nalorphine is at best only partial. The mechanism for this is neatly explained by Kallos and colleagues (1972) on the basis of the competitive dualism theory. The antagonist competes with the narcotic for the narcotic receptor sites and, because of its relatively greater receptor affinity, tends to displace the narcotic and occupy the receptor. The resulting effects then depend on the degree of receptor activity (intrinsic agonist effects) of the antagonist. Thus, nalorphine can never produce complete reversal because its own intrinsic agonist effects will always present as residual depression. Naloxone, however, is superior to nalorphine, first because its greater receptor affinity means it is a more potent antagonist, and second, having no receptor activity, it is capable of producing complete reversal of narcotic depression.
Therefore naloxone is a pure competitive antagonist. A further clinical implication is that if the depression for which the antagonist is prescribed has other causes in addition to the effect of narcotics, such as other drugs or neurological or muscular dysfunction, then nalorphine may make the depression worse by addition of its own intrinsic depressant effects. This may explain the finding in this study that large doses of nalorphine can increase the respiratory depression produced by a combination of fentanyl and droperidol.
The finding that naloxone only partially reverses the respiratory depression produced by a combination of fentanyl and droperidol may be explained by consideration of figure 5. Naloxone 1 mg/kg will completely antagonize the respiratory depression of 160-, fentanyl alone (up to 0.4 mg/kg) as shown in figure 1A . However, when used against the combination of fentanyl and droperidol, a residual depression remains which is equal to the depression produced by the same dose of droperidol alone. On the other hand, since droperidol itself is not analgesic, the analgesic effects of the combination are completely reversed. Evans and others (1974b) have emphasized the short duration of the antagonist effects of naloxone after a single injection, stressing that, after an initially adequate reversal, respiratory depression may return should the duration of action of naloxone be shorter than that of the narcotic. This effect was not seen in this study because fentanyl has a short duration of action which did not outlast the antagonistic effects of naloxone, at least in respect of its respiratory effects. On the other hand, a return of analgesia noted after 45-60 min following a single dose of naloxone and one of the larger doses of fentanyl suggests that naloxone has a shorter duration of antagonist activity against analgesic effects than against respiratory effects. This adds some support to the controversial suggestion by Hasbrouck (1971) and Heisterkamp and Cohen (1974) that, following large doses of a narcotic and naloxone, it is possible to observe reversal of respiratory depression and retention of analgesia. This suggestion is not supported by Evans and others (1974b) .
Bearing in mind the limitations of applying results from work in animals directly to the human situation, cautious consideration can be given to the possible clinical relevance of this discussion.
If a narcotic antagonist is required to reverse depression produced by fentanyl alone, then naloxone would appear to be superior to nalorphine because it is a more effective antagonist and is also free from intrinsic agonist effects. In fact, in view of the mass of evidence accumulated in the literature, there can no longer be any justification for the continued use of partial agonists like nalorphine as narcotic antagonists situations where naloxone is available as an in alternative. Naloxone should now be recognized as the drug of choice. However, the orthodox view that adequate reversal of respiratory depression must of necessity be accompanied by loss of analgesia must still stand, although further evidence to support Heisterkamp and Cohen (1974) in their opposing viewpoint is awaited with interest. More problematical is the position of narcotic antagonists when droperidol has been used with fentanyl. On the basis of this study caution ought to be exercised in the use of naloxone in these circumstances as complete abolition of analgesia may result, with the retention of significant respiratory depression which is likely to be quite the opposite of what is desirable clinically.
COMPARAISON FAITE SUR DES SOURIS DU NALOXONE ET DE LA NALORPHINE UTILISES EN TANT QU'ANTAGONISTES AUX MEDICAMENTS NEUROLEPTANALGESIQUES

RESUME
On compare dans cette communication l'efficacite du naloxone et de la nalorphine en tant qu'antagonistes des effets du fentanyl et du droperidol sur le temps de reaction de la plaque chaude et la frequence respiratoire de la souris. Le naloxone s'est montre superieur a la nalorphine, etant un antagoniste plus efficace, et etant aussi exempt de tout effet agoniste. Neanmoins, aucun des deux antagonistes n'a ete totalement efficace contre la depression de la frequence respiratoire produite par les combinaisons de fentanyl et de droperidol. II est suggere que la duree des effets antagonistes du naloxone sont plus courts contre la depression respiratoire que contre l'analgesie. 
SUMARIO
Se ha comparado la eficacia de naloxona y nalorfina en antagonizar los efectos de fentanil y droperidol sobre el tiempo de reaction en placa caliente y frecuencia respiratoria del raton. Naloxona fue superior a nalorfina, constituyendo un antagonista mas eficaz ademas de estar exento de efectos agonistas significantes. Sin embargo, ninguno de los dos antagonistas fue completamente eficaz contra la depresion sobre la frecuencia respiratoria, resultado de las combinaciones de fentanil y droperidol. Se sugiere que la duration de los efectos antagonizantes de la naxolona son mas breves contra la depresi6n respiratoria que contra la analgesia.
